Impact	O
of	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
on	O
outcome	O
in	O
patients	O
with	O
advanced	B:C0030297
pancreatic	I:C0030297
cancer	I:C0030297
not	O
receiving	O
nab	B:C1527223
-	I:C1527223
paclitaxel	I:C1527223
:	O
a	O
pooled	O
analysis	O
from	O
prospective	O
clinical	B:C0008976
and	O
translational	B:C3494163
trials	I:C3494163
.	O

Conflicting	O
results	O
on	O
the	O
role	O
of	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
(	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
)	O
expression	B:C1171362
have	O
been	O
reported	O
in	O
resected	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
pancreatic	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
)	O
,	O
and	O
its	O
prognostic	B:C0220901
and	O
/	O
or	O
predictive	O
role	O
in	O
advanced	B:C1335302
PDAC	I:C1335302
(	O
advanced	B:C1335302
PDAC	I:C1335302
)	O
has	O
not	O
been	O
extensively	O
investigated	O
yet	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
as	O
a	O
biomarker	B:C0005516
in	O
advanced	B:C1335302
PDAC	I:C1335302
patients	O
(	O
pts	O
)	O
not	O
receiving	O
nab	B:C1527223
-	I:C1527223
paclitaxel	I:C1527223
.	O

Using	O
immunohistochemistry	B:C0021044
,	O
we	O
examined	B:C0332128
the	O
stromal	B:C0162597
as	O
well	O
as	O
the	O
tumoral	B:C0597032
(	O
i.e.	O
,	O
cytoplasmic	B:C0521449
)	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
in	O
tumour	B:C0475358
tissue	I:C0475358
(	O
primary	B:C0027667
tumours	I:C0027667
and	O
metastases	B:C0027627
)	O
of	O
134	O
advanced	B:C1335302
PDAC	I:C1335302
pts	O
participating	O
in	O
completed	O
prospective	O
clinical	B:C0008976
and	O
biomarker	B:C1879847
trials	I:C1879847
.	O

The	O
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
levels	O
were	O
correlated	O
to	O
the	O
pts	O
'	O
clinicopathological	O
parameters	O
and	O
survival	B:C2919552
times	I:C2919552
.	O

Sixty	O
-	O
seven	O
per	O
cent	O
of	O
the	O
analysed	O
tumours	B:C0027651
showed	O
high	O
stromal	B:C0162597
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
,	O
which	O
was	O
not	O
associated	O
with	O
overall	O
survival	O
(	O
OS	O
,	O
median	B:C0549183
9.1	O
vs	O
7.6	O
months	O
,	O
P=0.316	O
)	O
.	O

A	O
positive	O
cytoplasmic	B:C0521449
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
was	O
detected	O
in	O
55	O
%	O
of	O
the	O
tumours	B:C0027651
and	O
correlated	O
significantly	O
with	O
inferior	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
,	O
6.2	O
vs	O
8.6	O
months	O
,	O
P=0.004	O
)	O
and	O
OS	O
(	O
7.8	O
vs	O
8.4	O
months	O
,	O
P=0.032	O
)	O
.	O

This	O
association	O
was	O
strongest	O
for	O
pts	O
,	O
where	O
primary	B:C0475358
tumour	I:C0475358
tissue	I:C0475358
was	O
examined	B:C0332128
(	O
PFS	O
:	O
6.7	O
vs	O
10.8	O
months	O
,	O
P=0.004	O
;	O
OS	O
:	O
7.9	O
vs	O
11.9	O
months	O
,	O
P=0.030	O
)	O
,	O
whereas	O
no	O
significant	O
correlation	O
was	O
detected	O
for	O
pts	O
,	O
where	O
only	O
metastatic	B:C0475358
tissue	I:C0475358
was	O
available	O
(	O
PFS	O
:	O
5.8	O
vs	O
6.6	O
months	O
,	O
P=0.502	O
;	O
OS	O
:	O
7.0	O
vs	O
7.8	O
months	O
,	O
P=0.452	O
)	O
.	O

In	O
pts	O
receiving	O
gemcitabine	B:C0045093
-	O
based	O
chemotherapy	B:C3665472
cytoplasmic	B:C0521449
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
was	O
significantly	O
associated	O
with	O
an	O
inferior	O
PFS	O
and	O
OS	O
(	O
PFS	O
:	O
6.2	O
vs	O
9.2	O
months	O
,	O
P=0.002	O
;	O
OS	O
7.3	O
vs	O
9.9	O
months	O
,	O
P=0.012	O
)	O
,	O
whereas	O
no	O
such	O
association	O
was	O
detected	O
for	O
stromal	B:C0162597
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
or	O
for	O
pts	O
receiving	O
fluoropyrimidine	B:C0596581
-	O
based	O
chemotherapy	B:C3665472
.	O

We	O
identified	O
cytoplasmic	B:C0521449
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
in	O
the	O
primary	B:C0027667
tumour	I:C0027667
as	O
a	O
biomarker	B:C0005516
associated	O
with	O
inferior	O
PFS	O
and	O
OS	O
in	O
advanced	B:C1335302
PDAC	I:C1335302
.	O

Cytoplasmic	B:C0521449
secreted	B:C3530142
protein	I:C3530142
acidic	I:C3530142
and	I:C3530142
rich	I:C3530142
in	I:C3530142
cysteins	I:C3530142
expression	B:C1171362
may	O
furthermore	O
act	O
as	O
a	O
negative	O
predictive	O
biomarker	B:C0005516
in	O
pts	O
treated	B:C0332293
with	I:C0332293
gemcitabine	B:C0045093
-	O
based	O
chemotherapy	B:C3665472
.	O

